No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients

Makoto Murata, Nobuhiko Emi, Noriyuki Hirabayashi, Motohiro Hamaguchi, Seiichi Goto, Atushi Wakita, Mitsune Tanimoto, Hidehiko Saito, Yoshihisa Kodera, Yoshihisa Morishita

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We retrospectively examined HA-1 typing with polymerase chain reaction using sequence-specific primers in 120 samples from 60 HLA-A2-positive Japanese bone marrow transplantation recipients who received short-term methotrexate and cyclosporin A for graft-versus-host disease (GVHD) prophylaxis and their HLA-identical sibling donors. HA-1-incompatible pairs were observed in 22% of the samples. The probability of developing acute GVHD (grade II to IV) in HA-1-incompatible and -compatible patients was 0% and 19%, respectively (P = .10). In a comparison between HA-1-incompatible and -compatible patients with standard-risk leukemia, in whom age, patient/donor sex, and use of a total body irradiationcontaining regimen were equivalent, the probability of developing acute GVHD (grade II to IV) was 0% and 10%, respectively (P = .38). No evidence of recurrent leukemia was observed in the HA-1-incompatible patients with standard-risk leukemia, compared with 37% in HA-1-compatible patients (P = .11). In conclusion, HA-1 incompatibility may not be a risk factor for grade II to IV acute GVHD in Japanese patients who receive methotrexate and cyclosporin A and undergo bone marrow transplantation from HLA-identical sibling donors.

Original languageEnglish
Pages (from-to)371-375
Number of pages5
JournalInternational Journal of Hematology
Volume72
Issue number3
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Graft vs Host Disease
Bone Marrow Transplantation
Siblings
Incidence
Leukemia
Tissue Donors
Methotrexate
Cyclosporine
HLA-A2 Antigen
Polymerase Chain Reaction

Keywords

  • BMT
  • Graft-versus-host disease
  • Graft-versus-leukemia effect
  • HA-1
  • Minor histocompatibility antigen

ASJC Scopus subject areas

  • Hematology

Cite this

No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients. / Murata, Makoto; Emi, Nobuhiko; Hirabayashi, Noriyuki; Hamaguchi, Motohiro; Goto, Seiichi; Wakita, Atushi; Tanimoto, Mitsune; Saito, Hidehiko; Kodera, Yoshihisa; Morishita, Yoshihisa.

In: International Journal of Hematology, Vol. 72, No. 3, 2000, p. 371-375.

Research output: Contribution to journalArticle

Murata, M, Emi, N, Hirabayashi, N, Hamaguchi, M, Goto, S, Wakita, A, Tanimoto, M, Saito, H, Kodera, Y & Morishita, Y 2000, 'No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients', International Journal of Hematology, vol. 72, no. 3, pp. 371-375.
Murata, Makoto ; Emi, Nobuhiko ; Hirabayashi, Noriyuki ; Hamaguchi, Motohiro ; Goto, Seiichi ; Wakita, Atushi ; Tanimoto, Mitsune ; Saito, Hidehiko ; Kodera, Yoshihisa ; Morishita, Yoshihisa. / No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients. In: International Journal of Hematology. 2000 ; Vol. 72, No. 3. pp. 371-375.
@article{573a0f753de54d85a331c8e08847b9c2,
title = "No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients",
abstract = "We retrospectively examined HA-1 typing with polymerase chain reaction using sequence-specific primers in 120 samples from 60 HLA-A2-positive Japanese bone marrow transplantation recipients who received short-term methotrexate and cyclosporin A for graft-versus-host disease (GVHD) prophylaxis and their HLA-identical sibling donors. HA-1-incompatible pairs were observed in 22{\%} of the samples. The probability of developing acute GVHD (grade II to IV) in HA-1-incompatible and -compatible patients was 0{\%} and 19{\%}, respectively (P = .10). In a comparison between HA-1-incompatible and -compatible patients with standard-risk leukemia, in whom age, patient/donor sex, and use of a total body irradiationcontaining regimen were equivalent, the probability of developing acute GVHD (grade II to IV) was 0{\%} and 10{\%}, respectively (P = .38). No evidence of recurrent leukemia was observed in the HA-1-incompatible patients with standard-risk leukemia, compared with 37{\%} in HA-1-compatible patients (P = .11). In conclusion, HA-1 incompatibility may not be a risk factor for grade II to IV acute GVHD in Japanese patients who receive methotrexate and cyclosporin A and undergo bone marrow transplantation from HLA-identical sibling donors.",
keywords = "BMT, Graft-versus-host disease, Graft-versus-leukemia effect, HA-1, Minor histocompatibility antigen",
author = "Makoto Murata and Nobuhiko Emi and Noriyuki Hirabayashi and Motohiro Hamaguchi and Seiichi Goto and Atushi Wakita and Mitsune Tanimoto and Hidehiko Saito and Yoshihisa Kodera and Yoshihisa Morishita",
year = "2000",
language = "English",
volume = "72",
pages = "371--375",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients

AU - Murata, Makoto

AU - Emi, Nobuhiko

AU - Hirabayashi, Noriyuki

AU - Hamaguchi, Motohiro

AU - Goto, Seiichi

AU - Wakita, Atushi

AU - Tanimoto, Mitsune

AU - Saito, Hidehiko

AU - Kodera, Yoshihisa

AU - Morishita, Yoshihisa

PY - 2000

Y1 - 2000

N2 - We retrospectively examined HA-1 typing with polymerase chain reaction using sequence-specific primers in 120 samples from 60 HLA-A2-positive Japanese bone marrow transplantation recipients who received short-term methotrexate and cyclosporin A for graft-versus-host disease (GVHD) prophylaxis and their HLA-identical sibling donors. HA-1-incompatible pairs were observed in 22% of the samples. The probability of developing acute GVHD (grade II to IV) in HA-1-incompatible and -compatible patients was 0% and 19%, respectively (P = .10). In a comparison between HA-1-incompatible and -compatible patients with standard-risk leukemia, in whom age, patient/donor sex, and use of a total body irradiationcontaining regimen were equivalent, the probability of developing acute GVHD (grade II to IV) was 0% and 10%, respectively (P = .38). No evidence of recurrent leukemia was observed in the HA-1-incompatible patients with standard-risk leukemia, compared with 37% in HA-1-compatible patients (P = .11). In conclusion, HA-1 incompatibility may not be a risk factor for grade II to IV acute GVHD in Japanese patients who receive methotrexate and cyclosporin A and undergo bone marrow transplantation from HLA-identical sibling donors.

AB - We retrospectively examined HA-1 typing with polymerase chain reaction using sequence-specific primers in 120 samples from 60 HLA-A2-positive Japanese bone marrow transplantation recipients who received short-term methotrexate and cyclosporin A for graft-versus-host disease (GVHD) prophylaxis and their HLA-identical sibling donors. HA-1-incompatible pairs were observed in 22% of the samples. The probability of developing acute GVHD (grade II to IV) in HA-1-incompatible and -compatible patients was 0% and 19%, respectively (P = .10). In a comparison between HA-1-incompatible and -compatible patients with standard-risk leukemia, in whom age, patient/donor sex, and use of a total body irradiationcontaining regimen were equivalent, the probability of developing acute GVHD (grade II to IV) was 0% and 10%, respectively (P = .38). No evidence of recurrent leukemia was observed in the HA-1-incompatible patients with standard-risk leukemia, compared with 37% in HA-1-compatible patients (P = .11). In conclusion, HA-1 incompatibility may not be a risk factor for grade II to IV acute GVHD in Japanese patients who receive methotrexate and cyclosporin A and undergo bone marrow transplantation from HLA-identical sibling donors.

KW - BMT

KW - Graft-versus-host disease

KW - Graft-versus-leukemia effect

KW - HA-1

KW - Minor histocompatibility antigen

UR - http://www.scopus.com/inward/record.url?scp=0034303403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034303403&partnerID=8YFLogxK

M3 - Article

C2 - 11185997

AN - SCOPUS:0034303403

VL - 72

SP - 371

EP - 375

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -